Mason Capital Management LLC has commenced a tender offer to acquire Forward Pharma A/S for DKK 74.8 million on May 14, 2024. Mason Capital acquire all the outstanding ADSs and Ordinary Shares in Forward Pharma A/S (the "Company") for a purchase price of DKK 3013.84 per ADS or DKK 0.76 per Ordinary Share. ADSs and Ordinary Shares tendered into or purchased pursuant to the Tender Offer will not be subject to withdrawal from the Tender Offer and Mason Capital may, at its option, purchase ADSs or Ordinary Shares validly tendered on one or more dates at any time upon the satisfaction or waiver of all the conditions to the Tender Offer described in the Tender Offer Materials.

Subject to all conditions to the Tender Offer having been satisfied or waived by Mason Capital, Mason Capital will purchase ADSs and Ordinary Shares that have been validly tendered or purchased by the Expiration Date no later than promptly following the Expiration Date. The Tender Offer is scheduled to expire on June 12, 2024. As on June 13, 2024, The Tender Offer, which was previously scheduled to expire on June 12, 2024, has been extended to June 26, 2024, unless the Tender Offer is further extended or earlier terminated.

As of June 12, 2024, 933 ADSs and no Ordinary Shares have been tendered into the Tender Offer.